Surrozen, Inc.

NASDAQ:SRZN

Biotechnology

Healthcare
$31.74 -4.74%

-$1.14 today

Market cap
$237.33M
Beta
0.51
P/E (TTM)
-0.7
EPS (TTM)
-$31.29
52W Low $8.00High $35.00

Volume 0.31M

Average 0.11M

SRZN Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Surrozen, Inc.NASDAQ: SRZN

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity turns negative

Q1 FY2026 total equity was -$278.15M, compared with $5.67M a year earlier.

Context

  • Total equity amounted to 230.4% of total assets at the end of Q1 FY2026, up 225.5 pp from a year earlier.
  • Total equity increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -5002.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$278.15M-48.1% QoQ
Last fiscal yearDec 2025
-$187.76M-778.2% YoY
Year agoMar 2025
$5.67M-5002.1% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-5002.1%——
1 year-778.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
(187.76M) USD
Year-over-year change
-778.2%

Total Equity vs competitors

How SRZN compares with its peers on the latest reported figures

  • SRZN's Mar 2026 total equity of -$278.15M is the lowest of the 8 companies compared; the peer median is $29.91M.
  • Its year-over-year change of -5002.1% is the lowest of 8, against a peer median of +29.3%.
  • Total equity amounts to 230.4% of total assets for SRZN, versus a peer median of 82.8%.
SRZN Competitors Peer median
Total Equity for SRZN and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SEERSeer, Inc.Mar 2026$241.48M -22.4%-16.6%88.7%
TILInstil Bio, Inc.Mar 2026$110.7M -23.6%-32.1%55.2%
IMMXImmix Biopharma, Inc.Mar 2026$84.36M +779.4%+92.4%88.0%
CGTXCognition Therapeutics, Inc.Mar 2026$29.91M +143.8%-5.2%82.8%
GLSIGreenwich LifeSciences, Inc.Mar 2026$5.27M +301.6%-48.6%50.2%
IRDOpus Genetics, Inc.Mar 2026-$45.84M -1003.5%-30.8%68.6%
AGENAgenus Inc.Mar 2026-$227.98M +29.3%—122.3%
SRZNSurrozen, Inc.Mar 2026-$278.15M -5002.1%—230.4%
Peer median (excluding SRZN) $29.91M+29.3%-23.7%82.8%

Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents33.09M24.69M36.04M34.57M89.25M
Short-term Investments68.76M51.15M000
Net Receivables01.98M2.15M2.54M208K
Inventory00000
Other Current Assets0756K580K671K2.11M
Total Current Assets105.19M81.31M41.13M38.93M91.56M
Property, Plant & Equipment (Net)9.38M6.9M3.86M8.36M6.43M
Goodwill00000
Intangible Assets00000
Long-term Investments21.66M0688K0688K
Tax Assets00000
Other Non-current Assets954K1.23M402K1.17M46K
Total Non-current Assets31.99M8.13M4.95M9.54M7.17M
Total Assets137.17M89.44M46.08M48.47M98.73M
Account Payables2.72M658K525K306K728K
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities589K581K292K191K289K
Total Current Liabilities13.57M9.73M7.15M7.32M9.93M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities8.3M326K115K55.89M271.21M
Total Non-current Liabilities13.9M3.7M997K62.53M276.56M
Total Liabilities27.47M13.43M8.15M69.85M286.49M
Common Stock4K0001K
Retained Earnings(142.65M)(178.65M)(221.7M)(285.26M)(527.29M)
Accumulated OCI(119K)(241K)000
Other Stockholders Equity00000
Minority Interest00000
Total Equity109.7M76M37.94M(21.38M)(187.76M)
Total Debt7.79M5.6M3.38M8.47M6.64M
Net Debt(25.3M)(19.09M)(32.66M)(26.1M)(82.61M)

Surrozen, Inc.

NASDAQ:SRZN

Intrinsic Alpha fair value

Locked

Current Price

$31.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.